Navigation Links
Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
Date:7/16/2012

JUPITER, Fla., July 16, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today unveiled its latest biofuels enzyme advancement, AlternaFuel® CMAX3™. This next generation product enables the production of cellulosic biofuels and bio-based chemicals from a wide range of renewable non-food feedstocks under broad operating conditions.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and CEO, Mark Emalfarb, stated, "The data supporting this product clearly demonstrates Dyadic's scientific capabilities to leverage our C1 technology platform to create enzyme mixtures whose performance rivals the leading biofuels enzyme product on the market. This is largely due to the inherent robustness and versatility of the C1 genome and expression system, both of which have considerable untapped potential. The results obtained with AlternaFuel® CMAX3™ are not only relevant for the production of biofuels but also for bio-based chemicals and biogas. Dyadic and its licensees are continuing to develop better performing enzymes to further reduce the total cost of producing advanced biofuels and other bio-based products."

Jan Wery, Science Director at Dyadic Netherlands, added, "AlternaFuel® CMAX3™ achieved a similar saccharification yield at pH 5.0 and substantially better results at pH 6.0 than those achieved by the current leading competitive biofuels enzyme product. Saccharification yield is defined as the relative amount of fermentable sugars released through enzymatic hydrolysis from lignocellulosic biomass such as agricultural feedstock and waste. This important parameter demonstrates the level of progress being made across the entire industrial enzyme industry in developing enzymes necessary for lignocellulosic biomass to replace petroleum in fuel and chemical production."

About AlternaFuel® CMAX3™

AlternaFuel® CMAX3™ is the latest generation of a cellulase and hemicellulase complex based on Dyadic's C1 platform technology which enables efficient conversion of multiple forms of non-food biomass into fermentable sugars at broad pH and temperature ranges that can be used to produce biofuels, bio-based chemicals, biogas and other bio-based products.

For more information on AlternaFuel® CMAX3™, please visit Dyadic's recently remodeled website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary C1 fungal production platform and other technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries. 

Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers.  Please visit Dyadic Netherland's website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
3. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
4. Hark! Group demonstrates first heralded single photon source made from silicon
5. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
6. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
7. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
8. Entinostat Demonstrates Activity in Hodgkins Lymphoma
9. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
10. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
11. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... BELL, Pa. , Jan. 24, 2017 Reha Technology ... at Project Walk – Boston . The need ... as much as it is widely accepted in the surgical space. ... to be an adjunct to traditional therapy and adding technology to ... operational efficiency and have higher gait training repetitions which has been ...
(Date:1/24/2017)... ... , ... Global Food Safety Resource (GFSR) is pleased to kick ... which company CEO Tina Brillinger says features a refreshed interface combined with improved navigation ... “We've spoken to many of our stakeholders and determined that in order to expand ...
(Date:1/24/2017)... Columbus, Ohio (PRWEB) , ... ... ... today announced the release of Version 5.0 of its award-winning CERF ... ELN is a 21CFR11 compliant, collaborative, knowledge asset manager used by laboratories, ...
(Date:1/24/2017)... SANTA CLARA, Calif. , Jan. 24, 2017  Frost & ... chairman of the Fonar Corporation, will receive special recognition at the ... , taking place March 19 to 21, 2017 at the Loews ... To register and download the event agenda for ... www.frost.com/medtech ...
Breaking Biology Technology:
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):